ClinicalTrials.gg
CompletedNCT02996682Updated Feb 26, 2019Results posted

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

A Phase 3 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 33 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
73rd of 174
102 · median 78
Started
2016
with 13 others
Phase 3
56 of 174
none open now
Registered
168th of 174
by date
Lead sponsor
15 of 174
Gilead Sciences

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 73rd largest by enrollment, is one of 14 that started in 2016, is one of 56 in phase 3, and was the 168th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection and decompensated cirrhosis.

03

Conditions studied

  • Hepatitis C Virus Infection

Keywords

  • Communicable Diseases
  • Hepatitis
  • Hepatitis C
  • Virus Diseases
  • Liver Diseases
  • Digestive System Diseases
  • Hepatitis, Viral, Human
  • Velpatasvir
  • RNA Virus Infections
  • Ribavirin
  • Sofosbuvir
  • Antiviral Agents
  • Antimetabolites
  • Molecular Mechanisms of Pharmacological Action
  • Anti-Infective Agents
  • Decompensated Cirrhosis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Chronic -infected males and non-pregnant/non-lactating females
  • Treatment naive or treatment experienced individuals
  • -Turcotte Score 7-12 at screening

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    SOF/VEL

    SOF/VEL for 12 weeks

    Drug: SOF/VEL

  • Experimental
    SOF/VEL + RBV

    SOF/VEL + RBV for 12 weeks

    Drug: SOF/VEL · Drug: RBV

Interventions

  • DrugSOF/VEL

    Drug pages: Sofosbuvir · Velpatasvir

    400/100 mg FDC tablet administered orally once daily

    Also known as: Epclusa®

  • DrugRBV

    Capsules administered orally in a divided daily dose

    Also known as: Rebetol®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Discontinued Treatment (SOF/VEL or RBV) Early Due to an Adverse Event

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  2. Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

    SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

    Time frame: Posttreatment Week 24

  3. Percentage of Participants Who Had HCV RNA < LLOQ by Visit While on Treatment

    Time frame: Up to 12 weeks

  4. Change From Baseline in HCV RNA

    Time frame: Baseline and up to 12 weeks

  5. Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score

    MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.

    Time frame: Baseline to Posttreatment Week 24

  6. Percentage of Participants With Improved and Worsened Child-Pugh-Turcotte (CPT) Class

    CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. CPT scores were calculated using prothrombin activation percentage for the coagulation parameter per Japan's standard.

    Time frame: Baseline to Posttreatment Week 24

  7. Percentage of Participants With Virologic Failure

    Virologic failure was defined as: Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment), or Relapse (HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement).

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Feb 26, 2019

Participant flow

Participants were enrolled at study sites in Japan. The first participant was screened on 26 December 2016. The last study visit occurred on 08 May 2018.

Participant flow — Overall Study
MilestoneSOF/VELSOF/VEL + RBV
Started5151
Completed5148
Not completed03
Withdrew: Death03

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
Percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)92.2 (81.1 to 97.8)92.2 (81.1 to 97.8)
Statistical analysis
  • SOF/VEL · 2-sided exact 1-sample binomial test · p = <0.001 (P-value was from the 2-sided exact 1-sample binomial test for the superiority of each treatment group over pre-specified rate of 1%.)
  • SOF/VEL + RBV · 2-sided exact 1-sample binomial test · p = <0.001 (P-value was from the 2-sided exact 1-sample binomial test for the superiority of each treatment group over pre-specified rate of 1%.)
PrimaryPercentage of Participants Who Discontinued Treatment (SOF/VEL or RBV) Early Due to an Adverse Event
Time frame:
Up to 12 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Treatment (SOF/VEL or RBV) Early Due to an Adverse Event
Percentage of participantsSOF/VELSOF/VEL + RBV
Discontinuation of SOF/VEL03.9
Discontinuation of RBVNA17.6
SecondaryPercentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
Percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)94.1 (83.8 to 98.8)96.1 (86.5 to 99.5)
SecondaryPercentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

Time frame:
Posttreatment Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
Percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)92.2 (81.1 to 97.8)92.2 (81.1 to 97.8)
SecondaryPercentage of Participants Who Had HCV RNA < LLOQ by Visit While on Treatment
Time frame:
Up to 12 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had HCV RNA < LLOQ by Visit While on Treatment
Percentage of participantsSOF/VELSOF/VEL + RBV
Week 245.151.0
Week 496.190.2
Week 8100.096.1
Week 12100.0100.0
SecondaryChange From Baseline in HCV RNA
Time frame:
Baseline and up to 12 weeks
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA
log10 IU/mLSOF/VELSOF/VEL + RBV
Change at Week 2-4.14 ± 0.573-4.33 ± 0.525
Change at Week 4-4.55 ± 0.696-4.65 ± 0.528
Change at Week 8-4.56 ± 0.705-4.70 ± 0.554
Change at Week 12-4.56 ± 0.705-4.70 ± 0.554
SecondaryPercentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score

MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.

Time frame:
Baseline to Posttreatment Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score
Percentage of participantsSOF/VELSOF/VEL + RBV
Decrease (Improvement)38.321.7
No Change53.254.3
Increase (Worsening)8.523.9
SecondaryPercentage of Participants With Improved and Worsened Child-Pugh-Turcotte (CPT) Class

CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. CPT scores were calculated using prothrombin activation percentage for the coagulation parameter per Japan's standard.

Time frame:
Baseline to Posttreatment Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Improved and Worsened Child-Pugh-Turcotte (CPT) Class
Percentage of participantsSOF/VELSOF/VEL + RBV
Improved CPT Class36.239.1
Worsened CPT Class4.32.2
SecondaryPercentage of Participants With Virologic Failure

Virologic failure was defined as: Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment), or Relapse (HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement).

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Failure
Percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants With Virologic Failure7.83.9

Adverse events

Collected over Adverse Events: Up to 12 weeks plus 30 days; All-Cause Mortality: Up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOF/VEL0/51 (0%)4/51 (7.8%)14/51 (27.5%)
SOF/VEL + RBV3/51 (5.9%)7/51 (13.7%)34/51 (66.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventSOF/VELSOF/VEL + RBV
Femur fractureInjury, poisoning and procedural complications0/512/51
Hepatic encephalopathyNervous system disorders1/512/51
AnaemiaBlood and lymphatic system disorders0/511/51
AscitesGastrointestinal disorders0/511/51
Gastric varices haemorrhageGastrointestinal disorders0/511/51
Oesophageal varices haemorrhageGastrointestinal disorders0/511/51
Varices oesophagealGastrointestinal disorders1/510/51
Bacterial sepsisInfections and infestations0/511/51
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/510/51
Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/510/51
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSOF/VELSOF/VEL + RBV
AnaemiaBlood and lymphatic system disorders0/5119/51
DiarrhoeaGastrointestinal disorders0/517/51
NasopharyngitisInfections and infestations7/513/51
Back painMusculoskeletal and connective tissue disorders0/514/51
HeadacheNervous system disorders1/514/51
InsomniaPsychiatric disorders0/514/51
RashSkin and subcutaneous tissue disorders4/511/51
Haemolytic anaemiaBlood and lymphatic system disorders0/513/51
ThrombocytopeniaBlood and lymphatic system disorders0/513/51
Oedema peripheralGeneral disorders3/512/51

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)SOF/VELSOF/VEL + RBVTotal
Mean66 ± 9.666 ± 9.666 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)SOF/VELSOF/VEL + RBVTotal
Female332962
Male182240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SOF/VELSOF/VEL + RBVTotal
Hispanic or Latino000
Not Hispanic or Latino5151102
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SOF/VELSOF/VEL + RBVTotal
American Indian or Alaska Native000
Asian5151102
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
HCV genotype
HCV genotype(Participants)SOF/VELSOF/VEL + RBVTotal
Genotype 1413980
Genotype 291120
Genotype 3101
Missing011
IL28b Status
IL28b Status(Participants)SOF/VELSOF/VEL + RBVTotal
CC333770
CT161329
TT213
HCV RNA (log10 international units per milliliter [IU/mL])
HCV RNA (log10 international units per milliliter [IU/mL])(log10 IU/mL)SOF/VELSOF/VEL + RBVTotal
Mean5.7 ± 0.705.8 ± 0.555.8 ± 0.63
HCV RNA Category
HCV RNA Category(Participants)SOF/VELSOF/VEL + RBVTotal
< 800,000 IU/mL303060
≥ 800,000 IU/mL212142

2 further baseline measures are reported on the registry.

08

Study locations

33 sites
  • Shimonoseki, Yamaguchi, Japan
  • Bunkyo, Japan
  • Chiba, Japan
  • Chuo, Japan
  • Ehime, Japan
  • Fukui, Japan
  • Fukuyama-shi, Japan
  • Hiroshima, Japan
  • Ibaraki, Japan
  • Ichikawa, Japan
  • Iizuka City, Japan
  • Iruma, Japan
  • Izunokuni, Japan
  • Kashibara, Japan
  • Kofu, Japan
  • Kumamoto-shi, Japan
  • Kurume, Japan
  • Kyoto, Japan
  • Miyazaki-shi, Japan
  • Morioka, Japan
  • Musashino, Japan
  • Nagoya, Japan
  • Nishinomiya, Japan
  • Okayama, Japan
  • Omura, Japan
  • Osaka, Japan
  • Sapporo, Japan
  • Sendai, Japan
  • Shimotsuga-gun, Japan
  • Suita, Japan
  • Takamatsu, Japan
  • Ube, Japan
  • Yamagata, Japan
09

References and documents

Publications

  • Takehara T, Kurosaki M, Tanaka Y, Tatsumi T, Ikeda F, Takikawa Y, et al. Sofosbuvir/Velpatasvir with or without Ribavirin for 12 Weeks in HCV-Infected Japanese Subjects with Decompensated Cirrhosis [Presentation]. 54th Annual Meeting of Japan Society of Hepatology; 2018 June 15; Osaka, Japan.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Feb 2018, 13 months.

Results were first posted in Feb 2019, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 13 months is close to that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2016
First posted
Dec 19, 2016
StartActual
Dec 26, 2016
Primary completionActual
Feb 13, 2018
CompletionActual
May 8, 2018
Results first posted
Feb 26, 2019
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02996682
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 19, 2016
Start date
Dec 26, 2016
Primary completion
Feb 13, 2018
Completion
May 8, 2018
Results posted
Feb 26, 2019
Last update
Feb 26, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion